about
Structural evolutions of salicylaldoximes as selective agonists for estrogen receptor betaEstrogen receptor ligands: a patent review update.CB2-selective cannabinoid receptor ligands: synthesis, pharmacological evaluation, and molecular modeling investigation of 1,8-Naphthyridin-2(1H)-one-3-carboxamides.Selective and potent agonists for estrogen receptor beta derived from molecular refinements of salicylaldoximes.Ceramide analogues in apoptosis: a new strategy for anticancer drug development.Highly selective salicylketoxime-based estrogen receptor β agonists display antiproliferative activities in a glioma model.New quinolone- and 1,8-naphthyridine-3-carboxamides as selective CB2 receptor agonists with anticancer and immuno-modulatory activity.Oxime-based inhibitors of glucose transporter 1 displaying antiproliferative effects in cancer cells.Rational design, synthesis and anti-proliferative properties of new CB2 selective cannabinoid receptor ligands: an investigation of the 1,8-naphthyridin-2(1H)-one scaffold.Antiproliferative activity and cell cycle analysis of 2-(3,5-dihydroxyphenyl)-6-hydroxybenzothiazole on MCF-7 breast and HCT-15 colon cancer cell lines.Synthesis of heterocycle-based analogs of resveratrol and their antitumor and vasorelaxing properties.Study of apoptosis induction and deoxycytidine kinase/cytidine deaminase modulation in the synergistic interaction of a novel ceramide analog and gemcitabine in pancreatic cancer cells.Monoaryl-substituted salicylaldoximes as ligands for estrogen receptor beta.Synthesis of a resveratrol analogue with high ceramide-mediated proapoptotic activity on human breast cancer cells.Development of an HPLC/UV assay for the evaluation of inhibitors of human recombinant monoacylglycerol lipase.BACE1 inhibitory activities of enantiomerically pure, variously substituted N-(3-(4-benzhydrylpiperazin-1-yl)-2-hydroxypropyl) arylsulfonamides.Synthesis and antiviral properties of novel analogues of monophosphate and diphosphate bioactive forms of acyclovir.Salicylaldoxime moiety as a phenolic "A-Ring" substitute in estrogen receptor ligands.7-Nitrobenzofurazan (NBD) derivatives of 5'-N-ethylcarboxamidoadenosine (NECA) as new fluorescent probes for human A(3) adenosine receptors.Synthesis, antifungal activity, and molecular modeling studies of new inverted oxime ethers of oxiconazole.4-[6-(Dansylamino)hexylamino]-7-methyl-2-phenyl-1,8-naphthyridine as a new potential fluorescent probe for studying A1-adenosine receptor.Conformationally restrained ceramide analogues: effects of lipophilic modifications on the antiproliferative activity.Salicylaldoxime derivatives as new leads for the development of carbonic anhydrase inhibitors.Synthesis of aniline-type analogues of farnesyl diphosphate and their biological assays for prenyl protein transferase inhibitory activity.Stable analogues of geranylgeranyl diphosphate possessing improved geranylgeranyl versus farnesyl protein transferase inhibitory selectivity.Stable propylphosphonic acid analogues of geranylgeranyl diphosphate possessing inhibitory activity on geranylgeranyl protein transferase.alpha-Naphthylaminopropan-2-ol Derivatives as BACE1 Inhibitors.A theoretical study to investigate D2DAR/D4DAR selectivity: receptor modeling and molecular docking of dopaminergic ligands.Carbazole-containing arylcarboxamides as BACE1 inhibitors.Synthesis of Stable Analogues of Geranylgeranyl Diphosphate Possessing a (Z,E,E)-Geranylgeranyl Side Chain, Docking Analysis, and Biological Assays for Prenyl Protein Transferase InhibitionTraditional Uses of Cannabinoids and New Perspectives in the Treatment of Multiple SclerosisSynthesis, biological activity and molecular modeling of new biphenylic carboxamides as potent and selective CB2 receptor ligandsDesign, synthesis and preliminary evaluation of 18F-labelled 1,8-naphthyridin- and quinolin-2-one-3-carboxamide derivatives for PET imaging of CB2 cannabinoid receptor1,2-Dihydro-2-oxopyridine-3-carboxamides: The C-5 substituent is responsible for functionality switch at CB2 cannabinoid receptorPhosphonomethylphosphorylmethyl(oxy)-analogues of geranylgeranyl diphosphate as stable and selective geranylgeranyl protein transferase inhibitorsMetabolically labile cannabinoid esters: A ‘soft drug’ approach for the development of cannabinoid-based therapeutic drugsApplication of An Improved HPLC-FL Method to Screen Serine Palmitoyl Transferase InhibitorsSynthesis of Anthranylaldoxime Derivatives as Estrogen Receptor Ligands and Computational Prediction of Binding Modes
P50
Q28306027-80AB7CFD-482D-42BB-B0D4-B54B81CC3512Q34347152-3DF51B04-1A85-40B9-A986-6E17634D997DQ34525138-82C6A163-E06A-462E-B04B-493B49C77FF4Q34930830-FF9CA42C-CD30-495C-A3C4-A5DA42178470Q35079308-EE060D23-79F2-4CA7-923F-0EA012E19C7BQ36175547-A62331A9-9D29-48D2-9A44-963DDC2D1A32Q38879833-424D3813-C2EF-4D59-B1F1-5720D748D9B5Q39066242-BF1D8058-E93D-41FD-987A-128012A4C51FQ39368198-F502749A-5C44-4568-9A71-145C5DAE76A8Q39570539-0FE1D0BD-7C22-4046-A24E-3740E818BBD9Q39664910-10AA5825-761A-482B-B2CD-904E024AD31FQ39693708-058B5081-4192-454E-AF3F-315433792B47Q40013982-D163FD9A-7D0B-4E0C-87B5-8E7935FEF008Q40357881-0272894E-A03B-4BBE-A063-710D7787B302Q41286853-6F4B2E49-4878-4B14-890A-9CD661A40D00Q42863775-59CA40AF-E27B-4DBD-B0BD-CDBD0B64A0CBQ43506637-1452D222-D043-44E6-BE58-5B2BBB9B7B17Q43799662-575D5E25-F9CB-434E-B355-2ACB7E84A9C8Q43803537-8A788822-4B1F-4B68-97FB-14E9E39BAD1AQ44181857-F017E3D0-04C5-4894-BD66-DA9531F7D063Q44208534-76C97912-BFEA-4E89-9225-3C305D7857DCQ44321160-9CBDA607-D0CF-4DD8-98C8-78FC96B12CBBQ44485853-7B3946D2-E551-4299-92F9-70A2438DA1F8Q44663650-3C631964-5DAC-41AB-B518-9B4BB07930AAQ44672403-67EBB4C7-DBC1-4D69-8995-84DA0718B44DQ45151280-74BE1095-1500-4F07-A1A6-1580BDF55846Q46378593-7523DD7C-ED2A-4EB9-ADB7-0F64D42B061DQ46945976-D1B2F643-D019-40B8-8C6F-A61F6AD225B5Q48852608-FC93EEB5-1ABD-4EF6-8E6D-777666A1C048Q57719443-89852922-3219-4C13-B0D5-63E69D11FA6EQ58775742-7A52F933-E2BE-4DCD-AFC3-8604F87869C7Q58855665-D8843361-ADF8-47DB-A6BC-7B636FFFE9DDQ59033461-7B301DD7-9E1D-4BF2-978A-3568A860F511Q59033475-4AB9A04E-C234-4F90-AC1D-30C5ABEF9AC1Q59173479-89D5F8F7-A4AE-4467-AEDF-977971D31411Q59215230-F903C776-C271-451D-A43F-18DDD2953753Q59247478-2C1D07EF-F012-45E7-9E66-71A67678484FQ60780326-03D78941-8CF2-4E12-A77C-40CDE790C781
P50
description
onderzoeker
@nl
researcher ORCID: 0000-0001-8832-8075
@en
name
Simone Bertini
@ast
Simone Bertini
@en
Simone Bertini
@es
Simone Bertini
@nl
type
label
Simone Bertini
@ast
Simone Bertini
@en
Simone Bertini
@es
Simone Bertini
@nl
altLabel
S Bertini
@en
SIMONE BERTINI
@en
prefLabel
Simone Bertini
@ast
Simone Bertini
@en
Simone Bertini
@es
Simone Bertini
@nl
P106
P1153
56248420400
P21
P31
P496
0000-0001-8832-8075